Market Pulse Archives

Nov. 18, 2021, 10:58 a.m. EST

Longeveron stock rockets on very heavy volume after upbeat FDA news

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Longeveron Inc. (LGVN)
  • X
    iShares Biotechnology ETF (IBB)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

Shares of Longeveron Inc. /zigman2/quotes/224642771/composite LGVN 0.00% blasted 120.9% higher on very active morning trading Thursday, after the biotechnology company said its Lomecel-B for the treatment of a congenital heart defect in infants (Hypoplastic Left Heart Syndrome) affecting about 1,000 babies a year was granted rare pediatric disease (RPD) designation by the Food and Drug Administration. Trading volume exploded to 112.0 million shares, compared with the full-day average of about 110,000 shares. The stock was both the biggest gainer and most active on major U.S. exchanges. The company said Lomecel-B is currently being evaluated in a Phase 2 trial. Despite the rally, the stock, which went public in February, was still trading well below the initial public offering price of $10 a share. The stock has now climbed 77.7% over the past three months, while the iShares Nasdaq Biotechnology ETF /zigman2/quotes/206189322/composite IBB +1.15% has slipped 8.8% and the S&P 500 /zigman2/quotes/210599714/realtime SPX +1.00% has gained 6.4%.

US : U.S.: Nasdaq
$ 7.42
0.00 0.00%
Volume: 89,015
Jan. 20, 2022 10:08a
P/E Ratio
Dividend Yield
Market Cap
$165.13 million
Rev. per Employee
US : U.S.: Nasdaq
$ 133.35
+1.52 +1.15%
Volume: 319,926
Jan. 20, 2022 10:08a
+45.47 +1.00%
Volume: 387.35M
Jan. 20, 2022 10:09a

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.